Hey, Tim Plaehn here.

Bitcoin just dipped.

Everyone’s watching the price. But they’re missing the real opportunity.

This could be the best buying moment we’ll see all year.

I’m not talking about buying Bitcoin itself…

I’ve found a simple way to turn this moment into weekly income without buying crypto, opening a Coinbase account, or trading options.

Just a $45 investment you could find in your brokerage account right now.

And you could set yourself up for your first payout as soon as next Thursday.

After that? Every Thursday. Like clockwork.

We’re talking potential payouts of $1,200 a month or more.

Click here to watch my Bitcoin Income Briefing. 

I’ll show you exactly how it works and why you need to act now to catch next week’s payout.

Talk soon,

Tim Plaehn
Chief Income Strategist, Investors Alley

---

Additional Reading from MarketBeat Media

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

Submitted by Thomas Hughes. First Published: 2/5/2026. 

Key Takeaways

• AbbVie’s February price pullback is a buy signal, as its catalysts include outperformance and better-than-expected guidance.
• Growth underpins cash flow and capital returns, with a yield topping 3% and a track record of distribution growth.
• Analysts and institutional trends indicate accumulation and potential for higher stock prices.

When the price of a high-quality stock such as AbbVie (NYSE: ABBV) falls despite a report showing growth, outperformance, and better-than-expected guidance, it is often a good buying opportunity.

The only question is how far the stock may pull back. In this case, it likely won’t be far: AbbVie is well supported by market dynamics, including institutional buying and steady analyst coverage that point to accumulation and a continued uptrend.

Starlink pre-IPO opportunity with this $30 stock (Ad)

A little-known stock could double as Elon Musk prepares to take Starlink public in what may be the biggest IPO in history. This company is a critical supplier to Starlink’s fast-growing satellite network. One analyst believes it’s positioned for significant upside as the IPO approaches. You can get the ticker symbol free in the first three minutes of a brief video—no credit card required.Watch the video to get the ticker now

The likely outcome is that this healthcare marketfinds a bottom in the $200 range and quickly rebounds to record levels. 

AbbVie Pulls Back After Beat-and-Raise Quarter, Strong Guidance

AbbVie delivered a solid Q4 2025, underscoring the strength of its portfolio and resilience after the Humira patent transition. While Humira sales fell roughly 26% year-over-year (YOY), the drug remains a blockbuster, contributing more than $1 billion in quarterly revenue. Systemwide growth was up 10% YOY and beat expectations. Segmentally, Immunology rose 18.3% on Skyrizi and Rinvoq (each up more than 30%), while Neurology gained 17.9%. Oncology and Aesthetics were modestly down (about 1%), but growth should resume as comps ease and new launches come online.

Margins remain healthy. Revenue growth combined with operational execution drove margin expansion and faster earnings growth. Adjusted earnings rose by more than 25% versus 10% top-line growth — a gap of over 15 percentage points — and benefited from roughly a 220-basis-point margin improvement. Guidance calls for $14.37 in adjusted EPS at the low end of the range, about $0.15 above MarketBeat’s consensus, suggesting management may be conservative. The company continues to focus on product optimization, higher-margin therapies, and operational efficiency.

Analysts and Institutions Accumulate AbbVie, Indicate Double-Digit Upside

The analysts’ response to 2026 guidance has been constructive, highlighting double-digit growth in key products and pipeline progress. Although there were no immediate consensus revisions the morning of the release, commentary is consistent with steady coverage, a firm Moderate Buy rating, and rising price targets. Consensus forecasts a move to $250 — roughly 25% upside from key support — enough for a fresh all-time high, while some high-end targets imply up to 50% upside.

Institutional activity is also bullish: institutions own more than 70% of the stock and bought on balance throughout 2025, with nearly $2 purchased for each $1 sold. That trend has continued into early 2026, providing market support and a tailwind for the share price. 

Dividends are another reason institutions and analysts favor the stock. Technically a Dividend King due to its historical relationship with Abbott Laboratories (NYSE: ABT), AbbVie pays out roughly 70% of earnings and yields more than 3% with shares near record highs.

The company is on track for its 13th dividend increase since the spin-off and has delivered about a 6% dividend compound annual growth rate, which appears sustainable. The primary investor risk is dilution; that risk is limited. Share count rises incrementally from share-based compensation, but those increases have been largely offset by share repurchases.

AbbVie Shows Support at Critical Levels 

AbbVie’s pullback, which exceeded 5%, is understandable, but the chance of a deeper decline seems limited. Early trading shows support at critical levels, suggesting the correction may already be over. In this scenario the stock should regain traction within weeks, if not days, and could reach the $250 consensus price target before midyear — with a bull case pushing toward $300.

Thank you for subscribing to Earnings360, a morning newsletter that summarizes quarterly earnings for public companies that trade on U.S. markets.

This email content is a paid advertisement for Investors Alley, a third-party advertiser of Earnings360 and MarketBeat. 

If you need help with your account, please don’t hesitate to email MarketBeat’s South Dakota based support team at contact@marketbeat.com.

If you no longer wish to receive email from Earnings360, you can unsubscribe.

© 2006-2026 MarketBeat Media, LLC. 
345 North Reid Place #620, Sioux Falls, S.D. 57103. United States of America..

Today’s Bonus Content: Wall Street is shifting how it values AI stocks (Click to Opt-In)